Brokerages Set Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) Target Price at $18.33

Eupraxia Pharmaceuticals Inc. (NASDAQ:EPRX) has been assigned a consensus recommendation of “Moderate Buy” from the eight analysts that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation, four have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $18.3333.

EPRX has been the subject of several analyst reports. Wall Street Zen cut shares of Eupraxia Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a research report on Tuesday, April 21st. Zacks Research upgraded shares of Eupraxia Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Thursday, May 7th. HC Wainwright reiterated a “buy” rating and set a $11.00 price target on shares of Eupraxia Pharmaceuticals in a research report on Monday, May 4th. Finally, Stifel Nicolaus initiated coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, May 21st. They set a “buy” rating and a $25.00 price target for the company.

Institutional Investors Weigh In On Eupraxia Pharmaceuticals

Several institutional investors have recently modified their holdings of EPRX. Vivo Capital LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $7,965,000. Affinity Asset Advisors LLC boosted its stake in Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock worth $11,504,000 after acquiring an additional 1,289,005 shares during the last quarter. Ally Bridge Group NY LLC bought a new position in Eupraxia Pharmaceuticals during the 3rd quarter worth approximately $5,398,000. Seven Fleet Capital Management LP bought a new position in Eupraxia Pharmaceuticals during the 1st quarter worth approximately $5,137,000. Finally, Redmile Group LLC bought a new position in Eupraxia Pharmaceuticals during the 1st quarter worth approximately $5,068,000.

Eupraxia Pharmaceuticals Stock Performance

EPRX opened at $6.48 on Friday. The company has a current ratio of 19.31, a quick ratio of 19.31 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $421.33 million, a PE ratio of -6.17 and a beta of 0.97. Eupraxia Pharmaceuticals has a 1-year low of $4.19 and a 1-year high of $9.32. The firm has a 50-day moving average price of $6.90 and a two-hundred day moving average price of $7.38.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last posted its quarterly earnings data on Tuesday, May 12th. The company reported ($0.23) earnings per share for the quarter, missing the consensus estimate of ($0.22) by ($0.01). As a group, equities analysts anticipate that Eupraxia Pharmaceuticals will post -0.86 earnings per share for the current fiscal year.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals, Inc (NASDAQ: EPRX) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for autoimmune and inflammatory diseases. The company’s core strategy centers on selectively expanding regulatory T cells (Tregs)—immune cells responsible for maintaining self-tolerance and limiting pathological inflammation—through its proprietary platform. Its lead therapeutic candidate is currently in Phase 1 clinical development in patients with systemic lupus erythematosus.

Based in Seattle, Washington, Eupraxia Pharmaceuticals conducts research and development activities across North America, collaborating with academic institutions and contract research organizations to advance its pipeline.